Medicare Advantage Prior Authorization Requirements for Otolaryngologic Procedures in 2021

被引:1
|
作者
Miller, Lauren E. [1 ]
Miller, Ashley L. [1 ,2 ]
Rocco, James W. [1 ]
Rathi, Vinay K. [1 ]
机构
[1] Ohio State Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Columbus, OH USA
[2] Nationwide Childrens Hosp, Dept Pediat Otolaryngol, Columbus, OH USA
关键词
denial; medical necessity; Medicare Advantage; Medicare Part B; prior authorization; revenue cycle; utilization management;
D O I
10.1002/ohn.931
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Little is known about the extent of prior authorization requirements in otolaryngology. We performed a secondary analysis of data comparing prior authorization (PA) policies across 5 major Medicare Advantage insurers to estimate the counterfactual proportion of 2021 Medicare Part B fee-for-service spending and utilization for commonly performed otolaryngologic procedures that would have required PA. The counterfactual proportion of spending (range: 20.4%-27.6%) and utilization (range: 1.8%-4.5%) requiring PA was relatively consistent across insurers and largely attributable to rhinologic procedures. However, PA requirements for specific services varied widely among insurers. Among the 70 (of 196; 35.7%) services subject to PA by any insurer, nearly half were subject to PA by a single insurer (n = 34; 48.6%). Only 10 (14.3%) services were subject to PA by 4 (n = 6; 8.6%) or 5 (n = 4; 5.7%) insurers. These discrepancies illustrate the challenges of navigating discordant insurer policies for otolaryngologists and raise concerns about the validity of certain PA requirements.
引用
收藏
页码:1601 / 1604
页数:4
相关论文
共 50 条
  • [1] Improving Prior Authorization in Medicare Advantage
    Anderson, Kelly E.
    Darden, Michael
    Jain, Amit
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (15): : 1497 - 1498
  • [2] The Extent and Growth of Prior Authorization in Medicare Advantage
    Neprash, Hannah T.
    Mulcahy, John F.
    Golberstein, Ezra
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (03): : E85 - E92
  • [3] Rule Tackles Medicare Advantage Marketing, Prior Authorization
    Harris, Emily
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (18): : 1543 - 1543
  • [4] VARIATIONS IN MEDICARE ADVANTAGE PRIOR AUTHORIZATION POLICIES FOR HIGH-COST ONCOLOGY IMMUNOTHERAPIES
    Dardouri, M.
    Presskreischer, R. M.
    Zemplenyi, A.
    Anderson, K. E.
    VALUE IN HEALTH, 2023, 26 (06) : S224 - S224
  • [5] Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage
    Gupta, Ravi
    Fein, Jay
    Newhouse, Joseph P.
    Schwartz, Aaron L.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 384
  • [6] Medicare Advantage Has Become Notorious for Prior Authorization-CMS and Lawmakers Are Taking Action
    Cahan, Eli
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (12): : 948 - 951
  • [7] Association Between Medicare and FDA Policies and Prior Authorization Requirements for Buprenorphine Products in Medicare Part D Plans
    Mark, Tami L.
    Parish, William
    Zarkin, Gary A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (02): : 166 - 167
  • [8] Evaluation of Prior Authorization in Medicare Nonemergent Ambulance Transport
    Contreary, Kara
    Asher, Andrew
    Coopersmith, Jared
    JAMA HEALTH FORUM, 2022, 3 (07): : E222093
  • [9] Prior Authorization, Quantity Limits, and Costs for Varenicline in Medicare
    Jiang, Changchuan
    Nipp, Ryan D.
    Hong, Arthur S.
    Shih, Ya-Chen Tina
    Xing, Jiazhang
    Mullins, Megan A.
    Yabroff, K. Robin
    Liao, Joshua M.
    JAMA NETWORK OPEN, 2025, 8 (03)
  • [10] Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021
    Nguyen, Thuy D.
    Chua, Kao-Ping
    Andraka-Christou, Barbara
    Bradford, W. David
    Simon, Kosali
    JAMA HEALTH FORUM, 2022, 3 (07): : E221821